Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain

NCT03337503 | Terminated Phase 2 DMC

• 1 other identifier: Cannabis Oil Study PPP005-001
• Study Type: interventional
• Target: 161
• Locations: 1 country
• Sites: 1

Brief Summary

Seeking for effective therapeutic strategies, the investigators are proposing to test the effectiveness of different formulations of medical cannabis oil to alleviate chronic pain, which was partially relieved with conventional prescriptions. Furthermore, the investigators would like to assess the effect of different formulations of medical cannabis oil on other symptoms associated to chronic pain like anxiety and depression, as well as insomnia and appetite. Finally, as recently recommended for clinical studies on medical cannabis, the investigators will examine the safety profile of different cannabis formulations focusing on the following elements: a real chronic administration with more than two weeks of treatment, a larger number of patients, and the clinical relevance of medical cannabis oil to change the amount and type of concomitant medications used to control chronic non-cancer and cancer pain.

Conditions

Chronic Pain

Outcome Measures

Primary Outcomes (2)

• Does the daily use of cannabis oil improves chronic pain

  Changes in pain as measured by the Brief Pain Inventory-Short Form (BPI-SF) scale. Scale range is 0 to 10; 0 (No pain) being the best rating to the maximal rating of 10 (Pain as bad as you can imagine).

  Change from Baseline in BPI-SF at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18.

• Does the daily use of cannabis oil improves chronic pain

  Changes in pain as measured by the Numerical Rating Scale (NRS). The NRS is a measure of the average weekly pain intensity score greater than on a 0 to 10 points scale where 0 is No Pain and 10 is the worst pain.

  Change from Baseline in NRS at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18.

Secondary Outcomes (6)

• Does the daily use of cannabis oil improve symptom burden

  Change from Baseline in ESAS-r-CS at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18.

• Does the daily use of cannabis oil reduce the severity of Treatment-Emergent Adverse Events (safety and tolerability).

  Change from Baseline in UKU-SERSP at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18.

• Does the daily use of cannabis oil improve cognition

  Change from Baseline in Mini-Cog at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18.

• Does the daily use of cannabis oil reduce the Profile of Mood States (POMS)

  Change from Baseline in POMS at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18.

• Does the daily use of cannabis oil improve the Hamilton Rating Scale for Depression (HAM-D)

  Change from Baseline in HAM-D at Weeks 1 and 6 and in follow-up phase at Weeks 10 and 18.

Study Arms (4)

THC and CDB in a 1 to 1 ratio

EXPERIMENTAL

Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals. 2.5 mg THC with 2.5 mg CBD capsule

Drug: THC and CDB in a 1 to 1 ratio

THC and CBD in a 1 to 2 ratio

EXPERIMENTAL

Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals. 2.5 mg THC with 5 mg CBD capsule

Drug: Experimental: THC and CBD in a 1 to 2 ratio

high CBD with trace THC

EXPERIMENTAL

Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals. 20 mg CBD with traces of THC

Drug: High CBD with trace THC oil

placebo

PLACEBO COMPARATOR

Post a self-titrating schedule of carrier oil, subjects take 1 capsule three times a day at 6 hour intervals. carrier oil capsule

Other: placebo

Interventions

THC and CDB in a 1 to 1 ratio DRUG

capsule containing cannabis oil

THC and CDB in a 1 to 1 ratio

Experimental: THC and CBD in a 1 to 2 ratio DRUG

capsule containing cannabis oil

THC and CBD in a 1 to 2 ratio

High CBD with trace THC oil DRUG

capsule containing cannabis oil

high CBD with trace THC

placebo OTHER

carrier oil capsule

placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent
• Adult patients (older than 18 years of age), male and female, with chronic non-cancer and cancer pain (at least 3 months in duration)
• Patients experiencing an average weekly pain intensity score greater than 4 on a 11 points NRS
• Subject agreed to follow the protocol
• Naïve cannabis patients with chronic non-cancer and cancer pain (not used cannabis in any presentation in the last 12 weeks)
• Patients receiving opioids and other concomitant pain medications should have a stable dose for the last 15 days.
• Normal cognitive status according to MiniCog
• Normal liver function (defined as aspartate aminotransferase 10-40 U/L and alanine aminotransferase 7-56 U/L)
• Normal renal function (defined as serum creatinine level \<133 µmol/L and Estimated Glomerular Filtration Rate (eGFR) greater than or equal to 60)
• Negative result on βhuman chorionic gonadotropin pregnancy test (if applicable)
• Ability to read and respond to questions in French or English.
• A female volunteer must meet one of the following criteria:
• If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 28 days prior to the first drug administration, during the study and for at least 60 days after the last dose.
• If of non-childbearing potential - should be surgically sterile or in a menopausal state
• A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must be surgically sterile or agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration.

You may not qualify if:

• Acute pain (less than 3 months in duration)
• Previous serious adverse event or hypersensitivity to cannabis or cannabinoids
• Inability to understand and comply with the instructions of the study
• Presence of significant cardiac disease (history of unstable ischemic heart disease, heart failure, severe and uncontrolled hypertension) that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction
• Current substance use disorder according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5)
• Life-time history of dependence on cannabis or diagnosis of cannabis use disorder (CUD) according to the DSM 5
• Life-time history of DSM 5 schizophrenia, bipolar disorder, or previous psychosis with or intolerance to cannabinoids
• Current or history of suicidal ideation
• Pregnant, breast-feeding or female patients of child-bearing potential and male patients whose partner is of child-bearing potential, unless willing to ensure that they or their partner use effective contraception
• Hepatic impairment (aspartate aminotransferase more than three times normal) or renal function impairment (serum creatinine level \>133 µmol/L, Estimated Glomerular Filtration Rate (eGFR) \<60)
• Cognitive impairment according to MiniCog
• The patient is currently using or has used cannabinoid based medications within 90 days of study entry and is unwilling to abstain for the duration of the study
• Positive urine drug screen for cannabinoids and other potential abuse substances (e.g. alcohol, cocaine, amphetamines and methamphetamines, unprescribed opioids)
• Participation in another clinical trial within 30 days of enrolment in our trial

Sponsors & Collaborators

• Santé Cannabis: lead
• Tetra Bio-Pharma: collaborator

Study Sites (1)

Santé Cannabis

Montreal, Quebec, H2L 3K9, Canada

Location

MeSH Terms

Conditions

Chronic Pain

Interventions

Dronabinol

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cannabinoids; Terpenes; Hydrocarbons; Organic Chemicals

Study Officials

• Antonio Vigano, MD, MSc

  McGill University

  PRINCIPAL INVESTIGATOR

• Maria Fernanda Arboleda, MD

  McGill University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 17, 2017
• First Posted: November 9, 2017
• Study Start: January 29, 2018
• Primary Completion: February 15, 2019
• Study Completion: February 15, 2019
• Last Updated: December 2, 2024

Record last verified: 2024-04

Locations

CA (1)